These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23907518)

  • 61. Subcutaneous metastases from melanoma: a discussion of clinical experience.
    Rutkowski P; Zdzienicki M; Kozak K
    Melanoma Manag; 2014 Aug; 1(1):31-40. PubMed ID: 30190808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Isolated regional therapy for advanced extremity soft tissue sarcomas.
    Deneve JL; Zager JS
    Surg Oncol Clin N Am; 2012 Apr; 21(2):287-99. PubMed ID: 22365520
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.
    Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C
    Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Regional therapies for locoregionally advanced and unresectable melanoma.
    Weitman ES; Zager JS
    Clin Exp Metastasis; 2018 Aug; 35(5-6):495-502. PubMed ID: 29736626
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recurrent cutaneous melanoma: a surgical perspective.
    Yeung RS
    Semin Oncol; 1993 Oct; 20(5):400-18. PubMed ID: 8211191
    [No Abstract]   [Full Text] [Related]  

  • 66. Management of in-transit melanoma metastases: a review.
    Nan Tie E; Henderson MA; Gyorki DE
    ANZ J Surg; 2019 Jun; 89(6):647-652. PubMed ID: 30414233
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Hyperthermic regional perfusion in malignant melanoma of an extremity].
    Andersson AP; Drzewiecki KT
    Ugeskr Laeger; 1992 Oct; 154(41):2815-9. PubMed ID: 1413222
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
    Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
    Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma.
    Raef HS; Friedmann AM; Hawryluk EB
    Paediatr Drugs; 2019 Apr; 21(2):71-79. PubMed ID: 30924056
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
    Belli F; Arienti F; Rivoltini L; Santinami M; Mascheroni L; Prada A; Ammatuna M; Marchesi E; Parmiani G; Cascinelli N
    Melanoma Res; 1992 Nov; 2(4):263-71. PubMed ID: 1490114
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hyperthermic isolated regional perfusion of the limb with carboplatin.
    Daryanani D; de Vries EG; Guchelaar HJ; van Weerden TW; Hoekstra HJ
    Eur J Surg Oncol; 2000 Dec; 26(8):792-7. PubMed ID: 11087648
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.
    Rashid OM; Sloot S; Zager JS
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1355-64. PubMed ID: 25176398
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities.
    Papa MZ; Klein E; Karni T; Koller M; Davidson B; Azizi E; Ben-Ari G
    Am J Surg; 1996 Apr; 171(4):416-20. PubMed ID: 8604833
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity.
    Duprat Neto JP; Mauro AC; Molina AS; Nishinari K; Zurstrassen CE; Costa OF; Belfort FA; Facure L; Fregnani JH
    ANZ J Surg; 2014 Sep; 84(9):677-82. PubMed ID: 22998400
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
    Eggermont AM
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
    [No Abstract]   [Full Text] [Related]  

  • 78. Isolated limb perfusion in regional melanoma.
    Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):373-84. PubMed ID: 16632221
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma.
    Beasley GM; Zager JS; Thompson JF
    Ann Surg Oncol; 2020 Jan; 27(1):35-42. PubMed ID: 31471842
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.